LivaNova (NASDAQ:LIVN) Lowered to Buy Rating by StockNews.com
LivaNova (NASDAQ:LIVN – Get Free Report) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a ...
Business Insider1mon
LivaNova’s Undervalued Growth Potential: Buy Rating Reinforced by Strong Financial Performance and Market Opportunities
Its products include VNS therapy system. oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, and cannulae. The company was founded on February 20, 2015 and is ...
ETF Daily News20d
LivaNova (NASDAQ:LIVN) Raised to “Strong-Buy” at StockNews.com
The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae ...
Taiwan News12d
Heart-lung Machine Market Size, Division, New Business Opportunities, Growth Rate, Development Trend And Feasibility Studies up to 2025-2033
The Global Heart-lung Machine Market, valued at approximately USD 2.18 billion in 2022, is projected to grow at a robust CAGR of more than 6.9% during the forecast period from 2023 to 2030. Read the ...